Nucleic acid-based universal vaccine and methods of use thereof
OwnerHuabin ZHU, Yangiun QIN +1inventors
InventorsHuabin ZHU, Yangiun QIN, Renhuan XU
Life of this patent
Estimating the term…
Abstract
Described herein are compositions including a nucleic acid sequence (e.g., mRNA) encoding an infection agent antigenic polypeptide and a nucleic acid sequence (e.g., mRNA) encoding at least one universal T-cell epitope (UTE), as well as compositions including a nucleic acid sequence (e.g., mRNA) encoding an infection agent antigenic polypeptide and at least one universal T-cell epitope, and methods for using the compositions.
Claims88
A composition comprising:
- a nucleic acid sequence encoding an infection agent antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A composition comprising:
- a nucleic acid sequence encoding an infection agent antigenic polypeptide and at least one universal T-cell epitope.
A composition comprising:
- a nucleic acid sequence encoding a feline coronavirus (FCOV) antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A composition comprising:
- a nucleic acid sequence encoding a feline coronavirus (FCoV) antigenic polypeptide and at least one universal T-cell epitope.
A composition comprising:
- a nucleic acid sequence encoding a coronavirus antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A composition comprising:
- a nucleic acid sequence encoding a coronavirus antigenic polypeptide and at least one universal T-cell epitope.
A composition comprising:
- a nucleic acid sequence encoding a herpes simplex virus (HSV-1 and/or HSV-2) antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A composition comprising:
- a nucleic acid sequence encoding a herpes simplex virus (HSV-1 and/or HSV-2) antigenic polypeptide and at least one universal T-cell epitope.
A nanoparticle comprising:
- a nucleic acid sequence encoding an infection agent antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A nanoparticle comprising:
- a nucleic acid sequence encoding an infection agent antigenic polypeptide and at least one universal T-cell epitope.
A nanoparticle comprising:
- a nucleic acid sequence encoding a feline coronavirus (FCOV) antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A nanoparticle comprising:
- a nucleic acid sequence encoding a feline coronavirus (FCOV) antigenic polypeptide and at least one universal T-cell epitope.
A nanoparticle comprising:
- a nucleic acid sequence encoding a coronavirus antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A nanoparticle comprising:
- a nucleic acid sequence encoding a coronavirus antigenic polypeptide and at least one universal T-cell epitope.
A nanoparticle comprising:
- a nucleic acid sequence encoding a herpes simplex virus (HSV-1 and/or HSV-2) antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A nanoparticle comprising:
- a nucleic acid sequence encoding a herpes simplex virus (HSV-1 and/or HSV-2) antigenic polypeptide and at least one universal T-cell epitope.
A vaccine comprising:
- a nucleic acid sequence encoding an infection agent antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A vaccine comprising:
- a nucleic acid sequence encoding an infection agent antigenic polypeptide and at least one universal T-cell epitope.
A vaccine comprising:
- a nucleic acid sequence encoding a feline coronavirus (FCOV) antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A vaccine comprising:
- a nucleic acid sequence encoding a feline coronavirus (FCOV) antigenic polypeptide and
- at least one universal T-cell epitope.
A vaccine comprising:
- a nucleic acid sequence encoding a coronavirus antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A vaccine comprising:
- a nucleic acid sequence encoding a coronavirus antigenic polypeptide and at least one universal T-cell epitope.
A vaccine comprising:
- a nucleic acid sequence encoding a herpes simplex virus (HSV-1 and/or HSV-2) antigenic polypeptide, and
- a nucleic acid sequence encoding at least one universal T-cell epitope.
A vaccine comprising:
- a nucleic acid sequence encoding a herpes simplex virus (HSV-1 and/or HSV-2) antigenic polypeptide and at least one universal T-cell epitope.
A method of enhancing an immune response generated by a nucleic acid vaccine, the method comprising:
- introducing a nucleic acid sequence encoding at least one universal T-cell epitope into the nucleic acid vaccine.
A method of enhancing an immune response generated by a nucleic acid vaccine, the method comprising:
- introducing a nucleic acid sequence encoding at least one universal T-cell epitope as set forth in Tables 1-5 into the nucleic acid vaccine.
Dependencies are inferred from the claim text.